Share Email Print

Proceedings Paper

Performance of a nonlaser light source for photodynamic therapy
Author(s): Colin Whitehurst; Karen T. Byrne; Colin Morton; James V. Moore
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Advances in short arc technology and optical filter coatings led to the design and construction of a table-top light source in 1989; the first viable and cost-effective alternative to a laser. The device can deliver over 3 W within a 30 nm band centered at any wavelength from 200 nm to 1200 nm at fluence rates of over 1 W cm-2. Its relative biological effectiveness (RBE) in vitro has been proven alongside an argon pumped dye laser and a copper vapor pumped dye laser. These in vitro tests showed an efficiency of hematoporphyrin derivative (HPD) induced cellular photoinactivation close to that of the argon/dye laser (RBE 100%), with a mean RBE for the lamp of 87 +/- 3% (p < 0.05). The lamp proved to be superior to that of the copper/dye laser system with an RBE of up to 150% at fluence rates above 50 mWcm-2. In vivo tests show that the extent and depth of tumor necrosis are comparable to that of an argon/dye laser. An in situ bioassay using tumor regrowth delay is currently underway. Early clinical trials show clearance of Bowen's disease and actinic keratosis using the same light fluences as costly PDT lasers.

Paper Details

Date Published: 1 March 1995
PDF: 6 pages
Proc. SPIE 2371, 5th International Photodynamic Association Biennial Meeting, (1 March 1995); doi: 10.1117/12.203398
Show Author Affiliations
Colin Whitehurst, Paterson Institute for Cancer Research (United Kingdom)
Karen T. Byrne, Paterson Institute for Cancer Research (United Kingdom)
Colin Morton, Western Infirmary (United Kingdom)
James V. Moore, Paterson Institute for Cancer Research (United Kingdom)

Published in SPIE Proceedings Vol. 2371:
5th International Photodynamic Association Biennial Meeting
Denis A. Cortese, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?